A Comparison Between Child-Pugh and Albumin-Bilirubin Scores

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

230 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-01-01

Study Completion Date

2018-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare Child-Pugh and Albumin-Bilirubin scores in patients with spontaneous rupture of hepatocellular carcinoma

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Management of Spontaneous Ruptured Hepatocellular Carcinoma

NCT03516890

Rupture, Spontaneous Rupture Liver Hepatocellular Carcinoma

COMPLETED

A New Prognostic Scoring System for Spontaneous Ruptured Hepatocellular

NCT03504358

Rupture, Spontaneous

COMPLETED

Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy

NCT02319863

Cancer Progression

UNKNOWN NA

A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC

NCT03313648

Hepatocellular Carcinoma Recurrent

UNKNOWN NA

Liver Transplantation for Hepatocellular Carcinoma Arising in Non-cirrhotic Liver: a Propensity Score-matched Retrospective Cohort Study of Two National Databases

NCT06364839

Hepatocellular Carcinoma, Non-cirrhotic Liver

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To compare Child-Pugh and Albumin-Bilirubin scores in patients with spontaneous rupture of hepatocellular carcinoma. And to determine which is better in predicting long-term survival and short-term survival.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rupture, Spontaneous Rupture Liver Hepatocellular Carcinoma Hepatic Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Surgical treatment

Patients who received liver resection or palliative surgery, such as microwave coagulation therapy, hepatic artery ligation, or suturing ligation.

Liver resection

Intervention Type PROCEDURE

Liver resection was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.

Non-surgical treatment

Patients who received transcatheter arterial embolization (or transcatheter arterial chemoembolization) or conservative treatment

Transcatheter arterial embolization

Intervention Type OTHER

Transcatheter arterial embolization or transcatheter arterial chemoembolization can localize the bleeding point and provide interventional embolization.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Liver resection

Liver resection was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.

Intervention Type PROCEDURE

Transcatheter arterial embolization

Transcatheter arterial embolization or transcatheter arterial chemoembolization can localize the bleeding point and provide interventional embolization.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be diagnosed as hepatocellular carcinoma pathologically; had a tumor rupture confirmed by Intraperitoneal exploration or clinical signs and symptoms in combination with imaging examination.

Exclusion Criteria

* Be diagnosed as not hepatocellular carcinoma pathologically；had repeated transcatheter arterial chemoembolization(TACE) or a long history (more than 1 year) of cancer treatment; loss of follow up or without complete data.

Minimum Eligible Age

15 Years

Maximum Eligible Age

76 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No